Latest news with #HealthcareConference
Yahoo
5 days ago
- Business
- Yahoo
RxSight, Inc. to Present at the Wells Fargo Healthcare Conference
ALISO VIEJO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Wells Fargo Healthcare Conference in Boston. RxSight's management is scheduled to present on Thursday, September 4, 2025, at 7:15 a.m. Pacific Time / 10:15 a.m. Eastern Time. A live and archived webcast of the presentation will be available at: About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at Company Contact:Shelley B. ThunenChief Financial Officersthunen@ Investor Relations Contact:Oliver MoravcevicVP, Investor Relationsomoravcevic@ in to access your portfolio
Yahoo
7 days ago
- Business
- Yahoo
Glaukos Announces Participation in Wells Fargo Healthcare Conference
ALISO VIEJO, Calif., August 13, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 10:15 a.m. ET in Boston, MA. A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at About Glaukos Glaukos ( is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases. View source version on Contacts Chris LewisVice President, Investor Relations & Corporate Affairs(949) 481-0510clewis@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-06-2025
- Business
- Yahoo
Drug pricing reform talks with US government lack clarity, industry executives say
By Bhanvi Satija and Christy Santhosh (Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly and Merck said at an industry conference on Tuesday. President Donald Trump issued an executive order last month directing drugmakers to lower the prices of their medicines to align with what other countries pay. According to the order, the administration was to set "most favored nation" price targets within 30 days. The Department of Health and Human Services has said it expects drugmakers in the U.S. to set prices for their products at the lowest price paid by other high-income countries. Lilly's chief financial officer, Lucas Montarce, said that it was not clear when a resolution on the pricing reform would be achieved. "It's hard to make any assumption about when, but they haven't shared with us any details at this time," said Montarce at the Goldman Sachs' Healthcare Conference. On Monday, Pfizer's chief executive Albert Bourla had said that the meetings with the Trump administration were focused on high-level ideas and not "digging into the substance." "Conversations are ongoing. No clarity yet on where it's going to go," said Merck's CEO Robert Davis. Davis added that Merck has discussed how to share the cost of drug innovation, both in the United States and other countries, with the administration. "But how does that all translate into an actionable plan in the near term? There's still a lot of dialog happening, so that's not as clear," he said. Lilly and Merck executives said that any pricing reforms would require regulatory changes or government-to-government actions. AbbVie's CEO also said that there was a "long way to go" before an agreement would be reached on the pricing reform. Sign in to access your portfolio
National Post
22-05-2025
- Business
- National Post
Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference
Article content VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chief Financial Officer Sam Eldessouky is scheduled to participate in the 2025 Jefferies Global Healthcare Conference in New York City on June 4, 2025, at 7:35 a.m. ET. Article content Article content A live webcast of the conference will be available on the Investor Relations section of the Bausch + Lomb website. Article content About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit and connect with us on Facebook, Instagram, LinkedIn, X and YouTube. Article content Article content Article content Article content Article content Contacts Article content Media Contact: Chris Clark (848) 360-1100 Article content Article content
San Francisco Chronicle
21-04-2025
- Business
- San Francisco Chronicle
JPMorgan commits $3.8 million to boost downtown S.F., expands office
JPMorgan Chase is committing $3.8 million in local philanthropic support this year to boost downtown San Francisco, while also expanding and renovating its local offices. The banking giant said Monday it would provide funding for small business loans and help them fill empty storefronts. The bank is supporting the downtown pop-up openings of Mexican restaurant Al Pastor Papi, clothing store Nooworks and art studio Craftivity through the Vacant to Vibrant program. JPMorgan renewed its lease at 560 Mission St. and expanded by 65,000 square feet to almost 280,000 square feet, with space for over 1,600 employees. The building, owned by CommonWealth Partners, will be renamed to JPMorganChase Center. The company is also retaining 125,000 square feet at One Front St., the former offices of First Republic Bank, which JPMorgan acquired in 2023. The bank called employees back to the office five days a week starting in March. The offices will be renovated with new collaboration spaces, a pantry and prayer and maternity rooms. New signs will be installed at 560 Mission St. The renovation is expected to create almost 500 construction jobs. 'San Francisco is a key growth market for JPMorganChase and we have been hard at work with local leaders, partners, and clients to understand how we can best deploy our resources and expertise to power continued economic growth across the city,' said Tim Berry, JPMorgan's global head of corporate responsibility, in a statement. The bank has nearly 7,000 employees in the Bay Area and is also part of the Downtown Volunteer Coalition and supports Advance SF's Clean & Safe Streets Program and the SF Chamber of Commerce's Safety Workshops Initiative. It also confirmed the return of its Healthcare Conference to Union Square in January 2026. In the Bay Area, the company plans to open seven Financial Centers, bank branches geared towards high net worth investors, this year. Its first local Financial Center opened last October at 111 Pine St. 'JPMorganChase is showing the kind of partnership San Francisco needs," said Mayor Daniel Lurie in a statement. 'My administration is focused on creating the conditions for growth downtown — through safer, cleaner streets and reforms to make permitting faster. The message is getting out, and San Francisco is on the rise.'
